Traws Pharma (TRAW) completes ratutrelvir COVID-19 study and targets flu prophylaxis

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that it has completed an ongoing study of ratutrelvir, a ritonavir-free potential treatment for mild-to-moderate COVID-19 in both PAXLOVID-eligible and ineligible patients. The company also outlined plans to pursue an additional indication for its antiviral tivoxavir marboxil as a prophylactic treatment for seasonal influenza. These updates were provided in a press release attached as Exhibit 99.1, which also includes forward-looking statements that the company cautions are subject to significant risks and uncertainties that could cause actual results to differ from current expectations.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001130598 0001130598 2026-01-26 2026-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 26, 2026

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-36020		22-3627252
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

12 Penns Trail

Newtown, PA 18940

(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive
Offices)

Not Applicable 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $.01 per share	TRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On January 26, 2026, Traws Pharma, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the completion of its ongoing study of ratutrelvir, a ritonavir-free potential treatment, in PAXLOVID^®-eligible and ineligible patients with mild-to-moderate COVID-19, and plans for additional indication for tivoxavir marboxil as a prophylactic treatment for seasonal influenza. A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference into this Item 8.01.

Forward-Looking Statements

This Current Report, including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates”, “expects”, “estimates”, “believes”, “will” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 26, 2026.
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 26, 2026	TRAWS PHARMA, INC.
	By:	/s/ Iain Dukes
		Iain Dukes
		Chief Executive Officer

FAQ

What did Traws Pharma (TRAW) announce in this 8-K filing?

Traws Pharma announced the completion of its ongoing study of ratutrelvir, a ritonavir-free potential treatment, in PAXLOVID-eligible and ineligible patients with mild-to-moderate COVID-19, and plans for an additional indication for tivoxavir marboxil as a prophylactic treatment for seasonal influenza.

What is ratutrelvir in the context of Traws Pharma (TRAW)?

Ratutrelvir is described as a ritonavir-free potential treatment being studied in PAXLOVID-eligible and ineligible patients with mild-to-moderate COVID-19.

What are Traws Pharma’s plans for tivoxavir marboxil?

Traws Pharma plans to pursue an additional indication for tivoxavir marboxil as a prophylactic treatment for seasonal influenza.

How did Traws Pharma (TRAW) communicate these developments?

The company issued a press release, filed as Exhibit 99.1 to the Form 8-K, and incorporated it by reference into the filing.

Does the Traws Pharma 8-K include forward-looking statements?

Yes. The filing states that it, including Exhibit 99.1, contains forward-looking statements identified by terms such as “anticipates”, “expects”, “estimates”, “believes”, and “will”, and notes that various risks and uncertainties could cause actual results to differ from those implied.

Where can investors find more detail on the Traws Pharma (TRAW) COVID-19 study and flu plans?

More detail is contained in the press release dated January 26, 2026, which is attached as Exhibit 99.1 to the Form 8-K.